REGENXBIO is a clinical-stage biotechnology company developing gene therapies using its adeno-associated virus (AAV) delivery platform for a range of diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Ancora | 40 | Holds (flat) | 1,000 | $11,980 | 0.0% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -2% | 23,854 | $285,771 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-08-27 | Ciongoli Gregory Austin | director | 102,603 | $949,381 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.